Free Trial

Jasper Therapeutics (JSPR) Competitors

Jasper Therapeutics logo
$2.40 -0.14 (-5.51%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$2.50 +0.10 (+4.17%)
As of 04:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

JSPR vs. NLTX, NVCT, CRBU, GNLX, CLYM, BTMD, GLSI, AVTX, ACTU, and MCRB

Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Neoleukin Therapeutics (NLTX), Nuvectis Pharma (NVCT), Caribou Biosciences (CRBU), Genelux (GNLX), Climb Bio (CLYM), biote (BTMD), Greenwich LifeSciences (GLSI), Avalo Therapeutics (AVTX), Actuate Therapeutics (ACTU), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical products" industry.

Jasper Therapeutics vs. Its Competitors

Neoleukin Therapeutics (NASDAQ:NLTX) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Neoleukin Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.77, indicating that its stock price is 177% more volatile than the S&P 500.

In the previous week, Jasper Therapeutics had 26 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 26 mentions for Jasper Therapeutics and 0 mentions for Neoleukin Therapeutics. Neoleukin Therapeutics' average media sentiment score of 0.00 beat Jasper Therapeutics' score of -0.19 indicating that Neoleukin Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Neoleukin Therapeutics Neutral
Jasper Therapeutics Neutral

Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neoleukin TherapeuticsN/AN/A-$57.56M-$3.11-5.46
Jasper TherapeuticsN/AN/A-$71.27M-$6.01-0.40

Neoleukin Therapeutics' return on equity of -37.22% beat Jasper Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Neoleukin TherapeuticsN/A -37.22% -30.91%
Jasper Therapeutics N/A -172.28%-128.34%

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Jasper Therapeutics has a consensus target price of $25.63, indicating a potential upside of 967.71%. Given Jasper Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Jasper Therapeutics is more favorable than Neoleukin Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Neoleukin Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Jasper Therapeutics
0 Sell rating(s)
4 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Jasper Therapeutics beats Neoleukin Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPR vs. The Competition

MetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$41.28M$3.16B$5.76B$10.50B
Dividend YieldN/A2.36%5.53%4.57%
P/E Ratio-0.4021.0476.0426.62
Price / SalesN/A252.06469.4291.51
Price / CashN/A46.3537.4661.85
Price / Book0.589.7813.676.45
Net Income-$71.27M-$52.73M$3.29B$271.57M
7 Day Performance3.00%3.16%1.83%2.61%
1 Month Performance-18.09%4.69%3.98%7.28%
1 Year Performance-88.99%16.37%78.13%29.60%

Jasper Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPR
Jasper Therapeutics
3.2939 of 5 stars
$2.40
-5.5%
$25.63
+967.7%
-88.9%$41.28MN/A-0.4020Trending News
Analyst Forecast
NLTX
Neoleukin Therapeutics
N/A$17.20
-7.9%
N/A-58.3%$161.65MN/A-5.5390High Trading Volume
NVCT
Nuvectis Pharma
2.2813 of 5 stars
$6.43
+2.6%
$15.33
+138.5%
-7.0%$159.61MN/A-5.508Positive News
CRBU
Caribou Biosciences
2.0736 of 5 stars
$1.93
+14.2%
$6.67
+245.4%
-2.1%$157.38M$9.99M-1.08100News Coverage
Positive News
GNLX
Genelux
0.9813 of 5 stars
$4.11
-1.2%
$20.33
+394.7%
+101.9%$157.14M$10K-4.7810
CLYM
Climb Bio
3.4891 of 5 stars
$2.32
+0.4%
$9.00
+287.9%
N/A$156.54MN/A-3.319Positive News
Analyst Forecast
BTMD
biote
2.8597 of 5 stars
$3.22
+1.9%
$6.00
+86.3%
-48.6%$156.23M$197.19M3.58194News Coverage
Positive News
GLSI
Greenwich LifeSciences
1.4296 of 5 stars
$11.80
+3.0%
$42.00
+255.9%
-24.8%$156.20MN/A-8.683
AVTX
Avalo Therapeutics
3.9522 of 5 stars
$11.70
-1.1%
$31.67
+170.7%
+16.3%$155.59M$440K0.0040
ACTU
Actuate Therapeutics
2.4619 of 5 stars
$7.09
+6.8%
$20.33
+186.8%
+3.3%$154.34MN/A0.0010Analyst Forecast
MCRB
Seres Therapeutics
3.3385 of 5 stars
$16.52
-5.3%
$73.67
+345.9%
-24.3%$152.77M$126.32M-3.59330News Coverage

Related Companies and Tools


This page (NASDAQ:JSPR) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners